Welcome to our dedicated page for R1 Rcm news (Ticker: RCM), a resource for investors and traders seeking the latest updates and insights on R1 Rcm stock.
R1 RCM Inc. (RCM) delivers technology-driven revenue cycle management solutions that help healthcare providers optimize financial performance. This news hub provides investors and industry professionals with timely updates on operational milestones, strategic partnerships, and financial developments shaping this healthcare IT leader.
Access official press releases and curated analysis covering earnings reports, technology innovations, regulatory compliance updates, and client success stories. Our repository simplifies tracking R1 RCM's progress in automating healthcare revenue cycles through AI-powered platforms and scalable operational models.
Key content areas include financial disclosures, partnership announcements with health systems, platform enhancements, and industry recognition. Bookmark this page for centralized access to verified information about R1 RCM's role in transforming healthcare financial operations.
R1 RCM (NASDAQ:RCM) announced that its subsidiary, Project Roadrunner Parent Inc., has filed a registration statement on Form S-4 for its proposed acquisition of Cloudmed, a leading provider of Revenue Intelligence solutions. The acquisition agreement, first disclosed on January 10, 2022, allows R1 shareholders to retain approximately 70% of the combined entity. Cloudmed equity holders will have an 18-month lockup period after the transaction closes, slated for Q2 2022, pending regulatory approvals. The registration includes a preliminary proxy statement with vital information about the deal.
R1 RCM (NASDAQ:RCM) released its 2021 Environmental, Social, and Governance (ESG) report, showcasing its commitment to sustainability and corporate responsibility. The report highlights several initiatives, including the launch of R1 Entri for patient engagement, a 100% rating on the Human Rights Campaign’s Corporate Equality Index, and goals for diverse leadership. The company plans to plant 10,600 trees in India over five years to enhance air quality. This effort aligns with top ESG frameworks like the UN Sustainable Development Goals, marking R1's dedication to improving healthcare experiences.
R1 RCM, a leader in technology-driven healthcare solutions, announced its management team will present at two key conferences in March 2022. The presentations are scheduled for:
- 42nd Annual Cowen Health Care Conference on March 8 at 2:10pm ET
- Barclays Global Healthcare Conference on March 16 at 3:20pm ET
A live audio webcast will be available on R1's website, with a replay accessible for 90 days. R1 RCM aims to enhance patient experience and financial performance for healthcare providers.
R1 RCM reported Q4 2021 revenue of $398.9 million, a 21.5% increase year-over-year. However, GAAP net income fell to $36.0 million, down 54.2% due to a prior year's gain on business disposition. Adjusted EBITDA rose to $95.1 million, marking a 51.7% growth. For the full year, revenue reached $1,474.6 million, a 16.0% increase, while GAAP net income was $97.2 million, down 17.0%. R1 anticipates 2022 revenue between $1,660 million and $1,700 million, with adjusted EBITDA of $385 million to $405 million.
MURRAY, Utah, Feb. 14, 2022 (GLOBE NEWSWIRE) -- R1 RCM (NASDAQ: RCM) will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 1:00 pm ET. The event will be accessible via a live audio webcast on R1's Investor Relations website, with a replay available for 90 days post-event. R1 RCM specializes in technology-driven solutions that enhance patient experiences and improve financial performance for healthcare providers, aiming to boost net patient revenue and reduce costs.
R1 RCM (NASDAQ:RCM) has been awarded the Best in KLAS® designation for the second consecutive year, recognizing its leadership in Ambulatory Revenue Cycle Management (RCM) services. This designation is based on feedback from numerous healthcare providers across the U.S. who highlighted R1's commitment to enhancing patient care and operational performance. R1 scored top marks for loyalty and service, with providers praising its responsiveness and operational efficiency, ultimately improving financial outcomes for physician groups.
R1 RCM Inc. (NASDAQ: RCM) announced that Alex Mandl will not seek re-election to its board during the upcoming annual meeting. Mandl has been a board member since 2013, serving as lead director since 2018 and chair of the audit committee since 2015. R1's leadership praised his invaluable contributions to the board. John B. Henneman, III has been appointed as the new lead director, effective immediately. R1 RCM focuses on technology-driven solutions that enhance the patient experience and financial performance for healthcare organizations.
R1 RCM Inc. (NASDAQ: RCM) will release its financial results for Q4 and the full year of 2021 on February 17, 2022, before market open. The company's management will hold a conference call on the same day at 8:00 AM ET to discuss the outcomes and future business outlook. Interested participants can dial in or join via webcast on the company's Investor Relations website. R1 RCM specializes in technology-driven solutions that enhance patient experience and improve financial performance for healthcare providers.
R1 RCM (NASDAQ:RCM) is enhancing its team by hosting a virtual career open house on January 25, 2022, to recruit over 80 technology roles, emphasizing its commitment to simplify healthcare. As a leader in revenue cycle management, R1 manages over $40B in net patient revenue annually. The company aims to address operational challenges in healthcare through automation and technology. R1's strategy includes strategic acquisitions to advance its digital solutions. This initiative reflects a dedication to improving patient outcomes and operational efficiency.
FAQ
What is the current stock price of R1 Rcm (RCM)?
What is the market cap of R1 Rcm (RCM)?
